Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy

by Ayad M. Al‐Katib, Hussein Gaith, Dahlia Sano, Sayf Al‐Katib, Michelle Bonnett, Zyad Kafri
Published 2020-09-01

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

by Zemene Demelash Kifle
Published 2021-09-01

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

by Irina V. Poddubnaya, Tatyana E. Bialik, Natalya N. Glonina, Olga B. Kalashnikova, Kamil D. Kaplanov, Valery A. Lapin, Nadezhda V. Medvedeva, Natalya B. Mikhailova, Tatyana N. Moiseeva, Evgeniy A. Nikitin, Tatyana I. Pospelova, Elena A. Stadnik
Published 2020-05-01

Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence

by Andrei A. Petrenko, Maria I. Kislova, Elena A. Dmitrieva, Eugene A. Nikitin
Published 2021-08-01

Targeted Treatment of Follicular Lymphoma

by Karthik Nath, Maher K. Gandhi
Published 2021-02-01

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

by Hussein A. Abbas, William G. Wierda
Published 2021-05-01

A Review on Newer Tyrosine Kinase Inhibitors and their Uses

by NITHU M KUMAR, MEENU MATHEW, KN ANILA, S PRIYANKA
Published 2018-08-01